Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ieramilimab - Novartis Oncology

Next Previous
X
Search
Drug Profile

Ieramilimab - Novartis Oncology

Alternative Names: Anti-LAG-3-monoclonal-antibody; Humanised IMP-701; IMP-701 humanised; LAG-525; NVP-LAG525

Latest Information Update: 28 Sep 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immutep Limited; Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Malignant melanoma; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Hong Kong (IV, Infusion)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Triple-negative-breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Netherlands (IV, Infusion)
  • 06 Feb 2023 Novartis terminates a phase Ib trial in Triple negative Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or grater) in USA, Australia, Hong Kong, Israel, Italy, Japan, Netherlands, Singapore and Spain (IV, infusion), based on sponsored decision (NCT03742349)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top